Chapin Davis Inc. Reduces Holdings in Eli Lilly and Company $LLY

Chapin Davis Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY) by 38.7% during the second quarter, Holdings Channel.com reports. The firm owned 1,749 shares of the company’s stock after selling 1,102 shares during the period. Chapin Davis Inc.’s holdings in Eli Lilly and Company were worth $2,098,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Farther Finance Advisors LLC raised its holdings in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares in the last quarter. Iams Wealth Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $754,000. Amundi increased its position in Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the period. May Hill Capital LLC raised its holdings in Eli Lilly and Company by 131.6% in the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Caisse Des Depots ET Consignations raised its holdings in Eli Lilly and Company by 17.3% in the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock worth $11,643,000 after purchasing an additional 1,600 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat: Revenue rose 48% year over year to $22.97 billion, surpassing the approximately $20.7 billion consensus estimate. Non-GAAP EPS was $8.38 versus expectations of about $6.06, while reported EPS was $7.94. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand drove growth: Mounjaro and Zepbound sales surged, with Mounjaro reportedly up 91% and the two products generating nearly two-thirds of quarterly revenue. Continued volume growth in diabetes and obesity treatments was the primary catalyst for the stock’s advance. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Outlook raised: Lilly increased 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and maintained EPS guidance of $35.50-$36.50. The improved outlook indicates management expects momentum to continue. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Additional commercial and pipeline support: CVS Health expanded its weight-management program through a Lilly partnership, while Lilly is widening early access to experimental obesity drug retatrutide. The FDA also granted breakthrough therapy designation to investigational cancer drug olomorasib, adding longer-term pipeline potential.
• Neutral Sentiment: Key investor concern: Management indicated that manufacturing capacity could become a bottleneck if GLP-1 demand continues to outpace supply. Lilly is working to expand production, but execution and competition remain important risks at the stock’s elevated valuation.

Eli Lilly and Company Trading Up 4.9%

NYSE:LLY opened at $1,170.30 on Thursday. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 41.57, a PEG ratio of 1.39 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company’s 50-day simple moving average is $1,156.45 and its 200 day simple moving average is $1,045.49.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $2.22. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts forecast that Eli Lilly and Company will post 34.71 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Barclays lifted their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Rothschild & Co Redburn upped their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Jefferies Financial Group increased their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.